Warren Calls to Break Up UnitedHealth After $3.3B Amedisys Deal Clears DOJ
As seen on the 24/7 Wall St. homepage on November 1, 2026.
The $3.3 billion Amedisys deal cleared DOJ review, but Warren's breakup push keeps legislative antitrust risk alive for UnitedHealth holders.
UnitedHealth already sells your insurance, employs your doctor, and manages your prescriptions. Now Trump's DOJ let them buy home health and hospice giant Amedisys for $3.3 BILLION – giving them MORE power to raise costs and deny care. We need to break up Big Medicine.
- Replies0
- Reposts0
- Likes1
Continue ReadingShow less
Senator Elizabeth Warren is pressing the case that UnitedHealth has grown too dominant across too many parts of the health care system, pointing to the Trump DOJ's clearance of its $3.3 billion acquisition of home health and hospice company Amedisys as the latest evidence.
Warren's argument is that UnitedHealth already occupies the insurance, physician employment, and pharmacy benefit sides of the business, and that adding Amedisys extends that reach into home health and end-of-life care. Her post explicitly frames the combination as giving the company more power to raise costs and deny care.
Sponsored
For investors holding UnitedHealth, the deal closing is a near-term positive in that the regulatory overhang has lifted. The risk that Warren's language keeps alive, however, is legislative: a sustained political push to break up large health conglomerates revives antitrust scrutiny that goes beyond any single transaction.
Amedisys shareholders, meanwhile, see their deal reach the finish line after the DOJ review concluded without a block. Warren's continued attention to the sector signals that the political environment around large health care consolidation is unlikely to cool, even with this transaction settled.